March 31, 1998
VIA EDGAR
- ---------
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: OXiGENE, Inc. - Form 12b-25, Notification of Late Filing of Form
10-K for the period ended December 31, 1997
-----------------------------------------------------------------
Ladies and Gentlemen:
On behalf of OXiGENE, Inc. (the "Company"), we hereby file Form 12b-25 in
order to extend the time for filing of the Company's Annual Report on Form 10-K
for the period ended December 31, 1997.
Simultaneously with this filing, we also are sending a copy of this Form
12b-25 to The Nasdaq Stock Market, Inc.
Please telephone the undersigned at (212) 504-6804 if you have any
questions or comments.
Very truly yours,
/s/ M. Andica Kunst
--------------------------
M. Andica Kunst
cc: OXiGENE, Inc.
The Nasdaq Stock Market, Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
- ----------------------------
OMB APPROVAL
OMB Number: 3235-0058
Expires: May 31, 1997
Estimated average burden
hours per response.....2.50
- ----------------------------
- -----------------
SEC FILE NUMBER
0-21990
- -----------------
- -----------------
CUSIP NUMBER
691828-10-7
- -----------------
(Check One): /X/Form 10-K /_/Form 20-F /_/Form 11-K /_/Form 10-Q /_/Form N-SAR
For Period Ended: December 31, 1997
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:------------------------------------
- --------------------------------------------------------------------------------
Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
- --------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- --------------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
OXiGENE, Inc.
- --------------------------------------------------------------------------------
Full Name of Registrant
- --------------------------------------------------------------------------------
Former Name if Applicable
One Copley Place, Suite 602
- --------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Boston, MA 02116
- --------------------------------------------------------------------------------
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)
(a) the reasons described in reasonable detail in Part
III of this form could not be eliminated without
unreasonable effort or expense;
(b) The subject annual report, semi-annual report,
transition report on From 10-K, Form 20-F, 11-K or
Form N-SAR, or portion thereof, will be filed on
/X/ or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly
report of transition report on Form 10-Q, or
portion thereof will be filed on or before the
fifth calendar day following the prescribed due
date; and
(c) The accountant's statement or other exhibit
required by Rule 12b-25(c) has been attached if
applicable.
PART III -- NARRATIVE
State below in reasonable detail the reasons why Form 10-K and Form 10-KSB,
20-F, 11-K, 10-Q Form 10-QSB, N-SAR, or the transition report or portion
thereof, could not be filed within the prescribed time period.
All information necessary to complete the filing has not yet been compiled.
(Attach Extra Sheets if Needed)
SEC 1344 (6/94)
PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Gerald A. Eppner (212) 504-6286
---------------------------- --------------- --------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s).
/X/ Yes /_/ No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
/_/ Yes /X/ No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
- --------------------------------------------------------------------------------
OXiGENE, Inc.
-----------------------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date March 27, 1998 By /s/ Bo A. Haglund
--------------------------------------- -------------------------------
Title: Chief Financial Officer
